Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma

Name: Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
Published: 2024
License: Public Domain

Regeneron Pharmaceuticals · 2024

ClinicalTrials.gov · Datasets · License: Public Domain · 2024

Open Source ↗

asthma

asthma, uncontrolled, severe exacerbations, type 2 inflammation, elevated blood eosinophils, increased fractional exhaled nitric oxide (feno), atopy and elevated immunoglobulin e (ige), interventional, phase4

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma

Related documents